<DOC>
	<DOCNO>NCT02307370</DOCNO>
	<brief_summary>The primary objective study prove safety effectiveness Spectranetics Turbo-Elite catheter atherectomy treatment infrainguinal artery catheter vessel size least 50 % .</brief_summary>
	<brief_title>Atherectomy By Laser Ablation With Turbo-Elite</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>PAD Rutherford Class 14 Patient able walk unassisted nonmotorized assistive device . Documented PAD ABI &lt; 0.9 previous intervention reoccurrence symptom Documented stenosis duplex ≥50 % Patient pregnant breast feeding . Evidence Acute Limb Ischemia within 7 day prior procedure . CVA &lt; 60 day prior procedure . MI &lt; 60 day prior procedure . Known contraindication aspirin , antiplatelet/anticoagulant therapy require procedure/follow . Known allergy contrast medium adequately premedicated prior study procedure . Uncontrolled hypercoagulability history HIT HITTS syndrome . Serum creatinine ≥ 2.5 mg/dL ( unless dialysisdependent ) within one day prior procedure . Patient simultaneously participate another investigational drug device study interfere 30 day Safety Endpoint . Previously identify severe calcium vessel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>